John S. Sundy

7.9k citations

85 papers · 4.6k indexed · 3 hit papers · h-index 37

Impact in

Nephrology top 0.2%
- Gout, Hyperuricemia, Uric Acid
Rheumatology top 0.5%
- Rheumatoid Arthritis Research and Therapies
- Urticaria and Related Conditions

Papers in

Nephrology 27
- Gout, Hyperuricemia, Uric Acid 26
Rheumatology 30
- Urticaria and Related Conditions 13
- Rheumatoid Arthritis Research and Therapies 11

Co-authors: Michael S. Hershfield Edna Scarlett Nancy J. Ganson Susan J. Kelly Michael A. Becker Herbert S. B. Baraf William J. Huang Peter E. Lipsky
Journals: Annals of the Rheumatic Diseases (13 papers)Journal of Allergy and Clinical Immunology (6 papers)Journal of Crohn s and Colitis (5 papers)The Journal of Immunology (4 papers)Arthritis Research & Therapy (4 papers)
Partner nations: United States Belgium Japan

In The Last Decade

John S. Sundy

84 papers receiving 4.4k citations

Hit Papers

align trajectories log scale

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial 2021 · 163 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 Annals of the Rheumatic Diseases
2019 JAMA
2011 JAMA

Peers

Countries citing papers authored by John S. Sundy

Since Specialization

Citations

This map shows the geographic impact of John S. Sundy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John S. Sundy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John S. Sundy more than expected).

Fields of papers citing papers by John S. Sundy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John S. Sundy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John S. Sundy. The network helps show where John S. Sundy may publish in the future.

Co-authors

The 25 scholars most cited alongside John S. Sundy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John S. Sundy Line = papers co-authored together John S. Sundy links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-Fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-Mediated Diseases Blood ·Julia Manasson, Liliana M. Sanmarco, Alex Pellerin, Jordan M. Anderson, Nathan Rollins, Jialong Wu, Agustín Plasencia, Andita Newton, Ryan Peckner, Xing Yi, Lukita Fahriana Fahriana, Miguel Fernandes de Lima Neto, John S. Sundy, Kevin L. Otipoby, Iván Mascanfroni	2024	3
2	Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial Annals of the Rheumatic Diseases ·René Westhovens, William F. C. Rigby, Désirée van der Heijde, D. W. T. CHING, William Stohl, Jonathan Kay, Arvind Chopra, Beatrix Bartók, F. Matzkies, Zhaoyu Yin, Ying Guo, Chantal Tasset, John S. Sundy, Angelika Jahreis, Neelufar Mozaffarian, Osvaldo Daniel Messina, Robert Landewé, Tatsuya Atsumi, Gerd R Burmester	2021	95
3	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial Annals of the Rheumatic Diseases ·Bernard Combe, Alan Kivitz, Yoshiya Tanaka, Désirée van der Heijde, J. Simón, Herbert S. B. Baraf, Uma Kumar, F. Matzkies, Beatrix Bartók, Lei Ye, Ying Guo, Chantal Tasset, John S. Sundy, Angelika Jahreis, Mark C. Genovese, Neelufar Mozaffarian, Robert Landewé, Sang‐Cheol Bae, 雅詩山際, Peter Nash Hit paper breakdown →	2021	163
4	P372 Effects of filgotinib on anaemia, thrombocytopenia and leukopenia: Phase 3 study results in patients with active rheumatoid arthritis and prior inadequate response/intolerance to biological DMARDs Journal of Crohn s and Colitis ·R. Besuyen, Mark C. Genovese, Kurt de Vlam, Jacques‐Eric Gottenberg, Kenneth Kalunian, Beatrix Bartók, YingMeei Tan, Ying Guo, Chantal Tasset, John S. Sundy, David Walker, Tsutomu Takeuchi	2020	1
5	Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results Queensland's institutional digital repository (The University of Queensland) ·Bernard Combe, Alan Kivitz, Yoshiya Tanaka, Désirée van der Heijde, F. Matzkies, Beatrix Bartók, Lei Ye, Ying Guo, Chantal Tasset, John S. Sundy, Neelufar Mozaffarian, Robert Landewé, Sang‐Cheol Bae, Edward Keystone, Peter Nash	2019	16
6	Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis European Respiratory Journal ·Stephen M. Humphries, Jeffrey J. Swigris, Kevin K. Brown, Matthew Strand, Qi Gong, John S. Sundy, Ganesh Raghu, Marvin I. Schwarz, Kevin R. Flaherty, Rohit Sood, Thomas G. O’Riordan, David A. Lynch	2018	71
7	Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis Clinical Therapeutics ·David Gossage, В. Б. Нечерда, Sagi Penzel, Hao Zheng, Yan Xin, Preeti Lal, Guang Chen, Victoria Smith, John S. Sundy	2017	43
8	Depressogenic vulnerability and gender-specific patterns of neuro-immune dysregulation: What the ratio of cortisol to C-reactive protein can tell us about loss of normal regulatory control Brain Behavior and Immunity ·Edward C. Suarez, John S. Sundy, Alaattin Erkanli	2014	39
9	The Clinical and Environmental Determinants of Airway Transcriptional Profiles in Allergic Asthma American Journal of Respiratory and Critical Care Medicine ·Ivana V. Yang, John K. Tomfohr, Jaspal Singh, Whittaker Wh, Harvey E. Marshall, Loretta G. Que, Erin McElvania, M J Walters, John S. Sundy, David A. Schwartz	2012	23
10	Pegloticase for treating refractory chronic gout Drugs of today ·Richard L. George, John S. Sundy	2012	7
11	Preventing and treating acute gout attacks across the clinical spectrum: A roundtable discussion Cleveland Clinic Journal of Medicine ·Brian F. Mandell, N. Lawrence Edwards, John S. Sundy, Peter A. Simkin, James C. Pile	2010	12
12	The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study Annals of the Rheumatic Diseases ·Robert Terkeltaub, John S. Sundy, H. Ralph Schumacher, Frederick T. Murphy, S. Bookbinder, Yongda Mo, Rachel Wu, Scott Mellis, Allen Radin	2009	230
13	Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout Arthritis & Rheumatism ·John S. Sundy, Nancy J. Ganson, Susan J. Kelly, Edna Scarlett, Llewelyn Yi Chang Tan, William J. Huang, Michael S. Hershfield	2007	169
14	Uricase and other novel agents for the management of patients with treatment-failure gout Current Rheumatology Reports ·John S. Sundy, Michael S. Hershfield	2007	37
15	Determinants of exhaled nitric oxide levels in healthy, nonsmoking African American adults Journal of Allergy and Clinical Immunology ·Marc C. Levesque, 澤田駒次郎, Ravindra P. Jategaonkar, Ya-Lei Yu, Michelle Alexandra Jahja, K. Alexander, Sallie D. Allgood, Marga Giménez Álvarez, Andrew S. Allen, John S. Sundy	2007	37
16	Update on nonsteriodal anti-inflammatory drugs Current Opinion in Rheumatology ·Stacy P. Ardoin, John S. Sundy	2006	23
17	Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase Arthritis Research & Therapy ·Nancy J. Ganson, Susan J. Kelly, Edna Scarlett, John S. Sundy, Michael S. Hershfield	2005	287
18	Direct costs of allergic rhinitis in the united states: Estimates from the 1996 medical expenditure panel survey Journal of Allergy and Clinical Immunology ·Amy Law, Shelby D. Reed, John S. Sundy, Kevin A. Schulman	2003	75
19	Leukemia Inhibitory Factor, Oncostatin M, IL-6, and Stem Cell Factor mRNA Expression in Human Thymus Increases with Age and Is Associated with Thymic Atrophy The Journal of Immunology ·Gregory D. Sempowski, Laura P. Hale, John S. Sundy, Janice M. Massey, Richard A. Koup, Daniel C. Douek, Dhavalkumar D. Patel, Barton F. Haynes	2000	233
20	Cytokines and adhesion molecules in the pathogenesis of vasculitis Current Rheumatology Reports ·John S. Sundy, Barton F. Haynes	2000	31

About John S. Sundy

John S. Sundy is a scholar working on Nephrology, Rheumatology, Genetics, Hematology and Biological Psychiatry, having authored 85 papers that have together received 4.6k indexed citations. Recurring topics across this work include Gout, Hyperuricemia, Uric Acid (26 papers), Chronic Lymphocytic Leukemia Research (16 papers), Case Reports on Hematomas (14 papers), Urticaria and Related Conditions (13 papers), Asthma and respiratory diseases (11 papers), Rheumatoid Arthritis Research and Therapies (11 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (6 papers). The work is most often cited by research in Nephrology (1.6k citations), Rheumatology (1.5k citations), Hematology (499 citations), Immunology (705 citations) and Genetics (282 citations). John S. Sundy has collaborated with scholars based in United States, Belgium and Japan. Frequent co-authors include Michael S. Hershfield, Edna Scarlett, Nancy J. Ganson, Susan J. Kelly, Michael A. Becker, Herbert S. B. Baraf, William J. Huang, Peter E. Lipsky, Robert A. Yood and Denise Jaggers. Their work appears in journals such as Annals of the Rheumatic Diseases, Journal of Allergy and Clinical Immunology, Journal of Crohn s and Colitis, The Journal of Immunology and Arthritis Research & Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact